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Abstract
Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) drive angiogenesis, and several VEGFR in-
hibitors are already approved for use as single agents or in combination with chemotherapy. Although there is a
clear benefit with these drugs in a variety of tumors, the clinical response varies markedly among individuals.
Therefore, there is a need for an efficient method to identify patients who are likely to respond to antiangiogenic
therapy and to monitor its effects over time. We have recently developed a molecular imaging tracer for imaging
VEGFRs known as scVEGF/99mTc; an engineered single-chain (sc) form of VEGF radiolabeled with technetium
Tc 99m (99mTc). After intravenous injection, scVEGF/99mTc preferentially binds to and is internalized by VEGFRs
expressed within tumor vasculature, providing information on prevalence of functionally active receptors. We now
report that VEGFR imaging readily detects the effects of pazopanib, a small-molecule tyrosine kinase inhibitor under
clinical development, which selectively targets VEGFR, PDGFR, and c-Kit in mice with HT29 tumor xenografts. Im-
munohistochemical analysis confirmed that the changes in VEGFR imaging reflect a dramatic pazopanib-induced
decrease in the number of VEGFR-2+/CD31+ endothelial cells (ECs) within the tumor vasculature followed by a
relative increase in the number of ECs at the tumor edges. We suggest that VEGFR imaging can be used for
the identification of patients that are responding to VEGFR-targeted therapies and for guidance in rational design,
dosing, and schedules for combination regimens of antiangiogenic treatment.
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Introduction
Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)
provide the proangiogenic signaling that is required for growth and
continued survival of endothelial cells (ECs) within the angiogenic
vasculature of primary tumors and metastatic lesions. The critical
role of VEGF/VEGFR signaling in the generation and maintenance
of the tumor vasculature has led to massive efforts to develop drugs,
such as antibodies against VEGF and VEGFRs, or small-molecule
inhibitors of VEGFR tyrosine kinase, designed to selectively inhibit
this pathway. Several antiangiogenic drugs are already approved for
clinical use, either as monotherapy or as part of a combination ther-
apy, and many clinical trials are in progress for approved and experi-
mental inhibitors of the VEGF/VEGFR signaling pathway [1,2].
Unfortunately, the benefit to a large percentage of patients from these
targeted drug treatments is still limited. This is most likely due to the
current lack of optimal ways to evaluate a particular targeted drug; for
example, how to identify which patient population would benefit
most from that drug [3–7]. The mechanisms that determine sensitiv-
ity and resistance of ECs to antiangiogenic drugs are both complex
and poorly understood [7]. There are several experimental models
in which antiangiogenic drugs induce relatively rapid regression of tu-
mor vascularization [8–13], underscoring the important relationship
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between VEGF/VEGFR signaling and EC viability within a tumor
[14]. However, in most experimental systems and, certainly, in pa-
tients, VEGF/VEGFR–directed drugs inhibit tumor growth, rather
than lead to tumor regression, suggesting that a sufficient number
of tumor ECs can survive and form functional blood vessels. Fur-
thermore, it seems that decline in tumor vascularization might be
transient and it is followed by an “adaptive revascularization,” as
defined by Bergers and Hanahan [7]. This phenomenon may be par-
ticularly important when antiangiogenesis treatment is interrupted
[14–21]. The ability to measure the dynamics of these processes
in vivo and their susceptibility to drug intervention may hold the
key to successful clinical application of VEGF/VEGFR–directed ther-
apies [5].
We have recently developed a family of tracers for assessing
VEGFR expression with different imaging modalities [22,23]. These
tracers are based on an engineered VEGFR ligand, a single-chain (sc)
VEGF composed of two fused 3-112 amino acid (aa) fragments of
VEGF121 and an N-terminal 15-aa Cys tag with a unique cysteine
residue for site-specific conjugation of various payloads [22,24]. Di-
rect radiolabeling of Cys tag in scVEGF with technetium Tc 99m
(99mTc) yields a stable radiotracer scVEGF/99mTc for single photon
emission computed tomography (SPECT) imaging, which rapidly
binds to and is internalized by VEGF receptors, providing imaging
information on the prevalence of VEGFR in tumor vasculature in
various tumor models [23].
We report here that SPECT imaging of VEGFR with scVEGF/
99mTc provides a highly sensitive approach to the analysis of the
complex dynamics of VEGFR expression and activity during the
treatment of HT29 xenografts with pazopanib, a small-molecule
tyrosine kinase inhibitor (targeting VEGFR, PDGFR, and c-Kit) cur-
rently under clinical development [25,26]. Changes in tracer uptake
seen at SPECT and autoradiography directly correlated with the
immunohistochemical analyses of the EC markers VEGFR-2 and
CD31 and suggest that scVEGF/99mTc imaging will be useful clin-
ically for the assessment of the therapeutic efficacy of current and
future antiangiogenic drugs.
Methods
Reagents
scVEGF and scVEGF/Cy (scVEGF site-specifically labeled with
Cy5.5-maleimide) were prepared at SibTech, as described previously
[22]. scVEGF/AlexaFluor594 was prepared at SibTech by site-specific
conjugation of AlexaFluor594-maleimide (Invitrogen, Carlsbad, CA) to
scVEGF, as described for synthesis scVEGF/Cy5.5 [22], followed by
reverse phase high-performance liquid chromatography purification.
Pazopanib [5-({4-[2,3-dimethyl-2H -indazole-6-yl) methylamino]2-
pyrimidinyl}amino)-2methylbenzenesulfonamide] was synthesized at
GlaxoSmithKline (Collegeville, PA). For tissue culture assays, pazopanib
was obtained in a purified powder and reconstituted in DMSO at a
concentration of 10 mM before use. For the tumor xenograft studies,
pazopanib was formulated in aqueous 0.5% hydroxypropylmethylcellulose
and 0.1% Tween 80.
Tissue Culture
HT29 cells were obtained from ATCC (HTB-38; Manassas, VA)
and maintained in McCoy’s 5A medium supplemented with 10%
FBS (Gibco, Carlsbad, CA). PAE/KDR cells, porcine aortic ECs ex-
pressing full-length human VEGFR-2, and wild-type PAE cells (de-
scribed in Backer et al. [22]) were maintained in Dulbecco’s modified
Eagle’s medium high-glucose (Invitrogen) supplemented with 10%
FBS (HyClone, Waltham, MA) and 2 mM L-glutamine.
In Vitro Cellular Uptake of scVEGF-Based Tracer
For quantitative uptake experiments, PAE/KDR and PAE cells were
plated in black clear bottom 96-well plates (BD Falcon, Franklin Lakes,
NJ) at 20,000 cells per well. Twenty hours later, cells were shifted to
fresh culture medium either with or without 1 μM pazopanib and in-
cubated for 1 hour in CO2 incubator. scVEGF/Cy was titrated in cul-
ture medium with or without 1 μM pazopanib, then added to cells in
corresponding triplicate wells, and incubated for 20 minutes under nor-
mal tissue culture conditions. Then media were removed, cells were
washed extensively with PBS, then with PBS containing 0.5 M NaCl,
fixed in fresh 4% ultrapure methanol-free formaldehyde (Polysciences,
Warrington, PA), air-dried, and tracer uptake was quantitated by imag-
ing plates in Starion FLA-9000 imager (FUJIFILM Medical Systems
USA, Woodbridge, CT). For microscopy, PAE/KDR cells were plated
on four-well chamber slides (Nunc, Rochester, NY), 50,000 cells per
well, incubated for 1 hour with or without 10 μM pazopanib, and
then for 20minutes with 5 nM scVEGF/AlexaFluor594, with or without
10 μM pazopanib. After extensive washing, cells were mounted in
Vectashield with 4′,6-diamidino-2-phenylindole (Vector Labs, Burlin-
game, CA) and observed under an AxioObserver Zeiss microscope (Carl
Zeiss MicroImaging, Inc, Thornwood, NY).
Mice
Protocol for the animal studies was approved by the Institutional
Animal Care and Use Committees at Stanford University. Five- to six-
week-old female Swiss nude mice (NSWNU-M-F; Taconic, Hudson,
NY) received HT29 (1.5-1.8 × 106 cells per mouse) subcutaneously
in the left flank regions. Pazopanib was given as gavage, twice daily
at 100 mg/kg, for a total dosage of 200 mg/kg daily. At the end of
the study, tumors were harvested, flash-frozen, and cryosectioned to
obtain 60-μm, 20-μm, and 7-μm sections.
Immunohistochemistry
Fluorescent immunostaining of 7-μm tumor cryosections for
VEGFR-2(KDR/Flk-1), CD31(PECAM), and VEGFR-1(Flt-1)
was done as described [22]. Slides were observed and digitized on
an AxioObserver Zeiss microscope using 43× oil and 5× objectives.
Chromogenic immunostaining of 20-μm cryosections for VEGFR2
and for CD31 was developed with VECTASTATIN Elite ABC Kit
and VIP Substrate Purple Kit (Vector Labs).
SPECT Imaging
scVEGF was radiolabeled with 99mTc to an activity of 200 μCi/μg
protein as described [23]. In all imaging experiments, a dose of 2 to
4 mCi of scVEGF/99mTc was injected into the retro-orbital venous
sinus in a volume of 100 to 220 μl (10-20 μg protein) followed by
imaging 2 hours later. Briefly, images taken with the following pa-
rameters: 64 steps, 360° rotation, 30 seconds per step, 2.7 cm field
of view, 0.5 mm pinhole collimator, 64 × 64 imaging matrix. Image
reconstruction and analyses were performed with standard Mirage
(Siemens, Malvern, PA) image processing software using OSEM re-
construction (20 iterations, 8 subsets), and no filter. Tumor uptake
analysis of SPECT imaging data was performed using parametric
three-dimensional regions of interest, interactively placed and sized,
as described elsewhere [30]. Regions of interest of a standard dose in a
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capillary tube and the whole of each tumor were drawn, and histogram
for counts versus number of voxels was obtained. Maximal tumor up-
take per voxel for each tumor was then defined as 100 counts (cts) per
voxel and recalculated values of cts per voxel were tabulated together
with percentile of corresponding voxels, defined as 100 × (number of
voxel with given cpm) / (total number of voxels). The average counts/
voxel for the upper 98th percentile of voxels were calculated from the
histograms of the whole of each tumor, and the counts/voxel at 50th
percentile were subtracted to correct for background activity. The
resulting average values of the upper 98th percentile of voxels (U-
98th%) was then used for comparison of uptake in the high uptake
areas for all tumors.
Soluble VEGFRs
Blood was collected from deeply anesthetized mice by cardiac
puncture through 21-G needle into 1-ml syringes containing 3.8%
Na citrate, pH 7.0. Collected blood was transferred into preweighed
microcentrifuge tubes, weighed to calculate the size of blood sample,
incubated on ice for 30minutes, and centrifuged at 4000g for 5 minutes
at 4°C. Clarified plasma was carefully collected, immediately frozen,
and stored at −80°C until testing. Concentrations of soluble VEGFR-1
and VEGFR-2 in murine plasma were determined by ELISA using
Quantikine kits from R&D Systems (Minneapolis, MN). Standard
calibration curve for each receptor was generated during the assay. All
samples were tested in duplicates. Because the levels of sVEGFR-1 varied
within an order of magnitude, we validated the sensitivity of the kit with
control soluble mouse VEGFR-1 and found it to be corresponding to the
manufacturer’s specifications (714 pg/ml of control VEGFR-1, which is
within expected range of 503-838 pg/ml). We therefore assumed that
the lower level of VEGFR-1 in HT-29–bearing Swiss mice might be
a model-specific characteristic.
Results
Pazopanib Does Not Inhibit VEGFR-2–Mediated
Internalization of scVEGF-Based Tracers
Because imaging with scVEGF/99mTc requires VEGFR-mediated
internalization of the tracer, and pazopanib inhibits VEGFR tyrosine
kinase activity, it was important to establish if tyrosine phosphoryla-
tion is required for internalization of scVEGF-based tracers. Studies
of mutant VEGFR-2 have indicated that tyrosine phosphorylation
is required for efficient internalization [27,28], whereas experiments
with a tyrosine phosphorylation inhibitor SU5416 demonstrated
that only intracellular processing of the receptors, but not their inter-
nalization, is phosphorylation-dependent [29]. In view of these
somewhat conflicting results, we explored whether pazopanib can
affect internalization of scVEGF-based fluorescent tracers in porcine
aortic ECs PAE/KDR. As we reported previously [22], PAE/KDR
cells, but not parental PAE cells without VEGFR-2, rapidly inter-
nalize scVEGF/Cy, indicating VEGFR-2–mediated tracer uptake.
Pazopanib inhibits human VEGFR-2 with a half maximal inhibitory
concentration of 30 ± 13 nM [25]. We found that at a concentra-
tion of 10 nM, it efficiently blocked scVEGF-induced VEGFR-2 tyro-
sine phosphorylation in PAE/KDR cells engineered to express 100,000
human VEGFR-2 per cell (Figure 1A). However, the dose-dependent
intracellular accumulation of scVEGF/Cy fluorescent tracer by these
cells was not affected in the presence of pazopanib, even after 1 hour
before incubating with as high as 1 μM of the inhibitor (Figure 1B).
Fluorescent microscopy with scVEGF/AlexaFluor594 tracer also indi-
cated similar internalization of the tracer in pazopanib-treated and
control PAE/KDR cells (Figure 1C ). Taken together, these results sug-
gest that it is unlikely that pazopanib would inhibit VEGFR-mediated
internalization of scVEGF/99mTc tracer in vivo.
SPECT Imaging of Pazopanib-Induced VEGFR Changes
For imaging studies, we used subcutaneous human colon cancer
HT29 tumors grown in Swiss nude mice, a model that has been re-
ported to be highly sensitive to treatment with pazopanib [25]. After
tumors were grown for 19 to 20 days, mice (n = 10) underwent
SPECT imaging with scVEGF/99mTc (day 0) and were then sepa-
rated into control and pazopanib-treated groups and reimaged at
days 5 and 15. As shown in Figure 2A for a representative control
mouse, in serial SPECT imaging on days 0, 5, and 15, we observed
a selective tracer uptake in the tumor area, with preferential accumu-
lation of the tracer at the edges of the tumor in the so-called angio-
genic rim (Figure 2A). In contrast, as shown in Figure 2A for a
representative pazopanib-treated mouse, there was a marked decrease
in the tracer uptake in tumor area on day 5 relative to day 0. This
decrease was followed by a resurgence of the tracer uptake on day 15
relative to day 5 (Figure 2A).
To characterize temporal changes in tracer uptake at the tumor
edges, a quantitative histogram analysis of each SPECT image was
performed as described elsewhere [30]. The average value of focal ac-
tivity expressed as counts/voxel was determined for the upper 98th
percentile of voxels (U-98th%) within a tumor. We found that, de-
spite tumor growth, the average U-98th% uptake values were not
statistically different from one another at day 0, 5, or 15 in control
mice undergoing serial SPECT imaging (Figure 2B). In contrast, in
pazopanib-treated mice, the average U-98th% uptake values de-
creased three-fold (n = 4, P = .001) at day 5 relative to day 0 and
1.5-fold (n = 3, P = .05) at day 15 relative day 0 (Figure 2B). The
1.8-fold increase (n = 3, P = .004) in the average U-98th% uptake
values from day 5 to day 15 reflected the relative resurgence of tracer
uptake observed by SPECT imaging (Figure 2A).
Importantly, a three-fold decrease in the average U-98th% uptake
values after 5 days of pazopanib treatment was observed when the dif-
ference in tumor weight in treated versus control mice was only 25%
(P = .016) (Figure 2C). However, relative resurgence in tracer uptake
after 15 days of pazopanib treatment was observed despite continu-
ous inhibition of tumor growth leading to an approximately two-fold
smaller tumor weight of treated versus control mice (P = .0001). Thus,
SPECT imaging with scVEGF/99mTc can detect pazopanib-induced
changes in tumor vasculature well before they affect tumor growth
and morphology.
Pazopanib-Induced Changes in scVEGF/ 99mTc Tracer
Uptake, as Seen by Autoradiography
To further characterize the effects of pazopanib on tracer uptake,
we compared autoradiographs of serial tumor sections obtained from
additional groups of 5- and 15-day treated and time-matching control
scVEGF/99mTc-injected mice. As shown in Figure 3, A and B, pref-
erential accumulation of radioactivity at the tumor edges was readily
detected on autoradiographs of serial sections from control mice. As
shown in Figure 3C , a 5-day pazopanib treatment resulted in a markedly
lower tumor edge tracer uptake in treated versus control mice (compare
Figure 3C and Figure 3A). However, as shown in Figure 3D, a 15-day
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pazopanib treatment resulted in a relative resurgence of tumor edge
uptake, when compared with a 5-day group (compare Figure 3D and
Figure 3C). In fact, as judged by autoradiography, some sections from
15-day treated mice demonstrated a level of tumor edge tracer uptake
comparable to that in time-matching control mice (compare Figure 3D
and Figure 3B). Thus, autoradiography analysis supported SPECT im-
aging finding of decrease and relative resurgence of scVEGF/99mTc tracer
uptake in the course of pazopanib treatment.
Immunohistochemical Analysis of Pazopanib-Induced
VEGFR Changes
The uptake of scVEGF/99mTc by VEGFR-expressing cells de-
pends on several parameters, such as the number of VEGFR sites
per cell, the number of VEGFR-overexpressing cells, efficacy of
scVEGF/99mTc–VEGFR complex internalization, and VEGFR re-
cycling. Furthermore, spatial distribution of those parameters defines
the heterogeneity in tracer uptake, including prominent uptake at
the tumor edges. To assess VEGFR distribution, tumors from con-
trol and treated mice were cryosectioned for immunohistochemical
analysis of VEGF receptors, VEGFR-1 and VEGFR-2, as well as
pan-endothelial marker CD31 (PECAM) that unambiguously iden-
tifies ECs. Double-fluorescent immunostaining established that, in
HT29 tumors, VEGFR-1 was not expressed on CD31-positive ECs
(Figure 4A). In contrast, VEGFR-2 was expressed exclusively on
CD31-positive ECs (Figure 4B). The density of CD31+/VEGFR-2+
cells was 2- to 2.5-fold higher in the vascularized areas at the tumor
edges relative to tumor center (Figure 4C , compared with Figure 4B).
Pazopanib treatment strongly affected both VEGFR-2 and CD31
immunostaining of tumor edge areas with distinctively different re-
sults observed in 5- and 15-day regimen groups. A 5-day regimen
resulted in a rather dramatic decrease in VEGFR-2 and CD31 im-
munostaining relative to control (Figure 4D), but there was a visible
resurgence in VEGFR-2 and CD31 immunostaining reflecting re-
vascularization at the tumor edges, which was particularly prominent
at the low-magnification images (Figure 4E ). Furthermore, in the
15-day treatment group, CD31 and VEGFR-2 immunostaining at
the edges of the tumor sections was about as prominent as for the
time cohorts of control mice. In contrast, pazopanib treatment did
not change VEGFR-1 immunostaining (Figure 4F ).
Unlike dynamic vascular remodeling at the tumor edges, the de-
crease in VEGFR-2 and CD31 immunostaining in the tumor center
areas detected at the 5-day group (Figure 5A) persisted after 15 days of
pazopanib treatment (Figure 5B). Quantitative analysis of immuno-
staining for CD31 and VEGFR-2 in central areas in high-magnification
fields (n = 5) confirmed a dramatic difference in marker staining in
treated groups for both treatment regimens (Figure 5C).
Figure 1. Pazopanib does not block VEGFR-2–mediated uptake of scVEGF-based fluorescent tracers. (A) Pazopanib blocks scVEGF-induced
VEGFR-2 tyrosine phosphorylation in PAE/KDR cells expressing 100,000 VEGFR-2 per cell. Cells were plated on 24-well plates, 75,000 cells
per well, in complete culture medium, and shifted to serum-free medium 6 hours later. Top panel: After overnight serum starvation, cells
were incubated for 10minutes at 37°Cwith 10 nMscVEGF, either alone or in the presence of pazopanib, then lysed and analyzed byWestern
blot analysis with phosphotyrosine-specific antibody (pY, clone PT-66; Sigma, St. Louis, MO). Bottom panel: To ensure equal protein load-
ing, the blot was stripped and reprobed with VEGFR-2–specific rabbit antiserum as described [22]. (B) Pazopanib does not inhibit dose-
dependent uptake of scVEGF/Cy by PAE/KDR cells. A 20-minute tracer uptake by PAE/KDR (∼105 VEGFR-2/cell) and PAE (no VEGFR-2) cells
in the presence or absence of 1 μM pazopanib (after 1 hour before incubation) was quantitated in triplicate wells using Starion FLA-9000
imager (FUJIFILM Medical Systems USA). (C) Pazopanib does not inhibit uptake of scVEGF/AlexaFluor594 fluorescent tracer by PAE/KDR
cells. A 20-minute tracer uptake by PAE/KDR cells in the presence or absence of 10 μMpazopanibwas visualizedwith an AxioObserver Zeiss
microscope, using 43× oil objective. Control, untreated cells; Rx, pazopanib-treated cells.
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Taken together, immunostaining analysis suggests that the decrease
in scVEGF/99mTc uptake on day 5 is due to pazopanib-induced de-
crease in the number of CD31+/VEGFR-2+ tumor ECs throughout
the tumor, including tumor edges. Conversely, a subsequent resur-
gence in scVEGF/99mTc uptake at the tumor edges on day 15 is sup-
ported by the resurgence of CD31+ and VEGFR-2+ ECs in the same
areas. It remains to be established if enhanced VEGFR-2 internaliza-
tion and/or receptor recycling in proliferating ECs also contribute to
enhanced tracer uptake.
Effect of Pazopanib on Circulating Soluble VEGFR-2 and
VEGFR-1 Receptors
Extracellular fragments of VEGFR-1 and VEGFR-2, so-called soluble
VEGF receptors (sVEGFRs), are present in blood. Thus, one could
assume that pazopanib treatment increases the level of soluble receptors,
which then sequester scVEGF/99mTc tracer, leading to decreased uptake
in tumor vasculature. To test this assumption, we measured the levels of
sVEGFR-1 and sVEGFR-2 in plasma of control and treated mice using
sensitive quantitative ELISA. The levels of soluble VEGFR-2 in control
Figure 3. Decrease and resurgence of scVEGF/99mTc uptake in the course of pazopanib treatment. Autoradiographs of serial 60-μm sec-
tions from individual tumors harvested from treated and control and treated mice after 5- (A, C) and 15-day (B, D) treatment regimens.
Figure 2. Pazopanib treatment affects scVEGF/99mTc tracer uptake. (A) Representative anterior oblique views of the tumors from control
and treated mice reconstructed from three-dimensional data sets obtained in serial SPECT imaging. (B) Pazopanib significantly affects
tracer uptake in areas of maximal activity. The average activity of the upper 98th percentile of voxels (U-98th%) was calculated from the
longitudinal SPECT imaging for each mouse on days 0, 5, and 15 for treated and time cohorts of control mice. (C) Tumor weights for
control and treated mice. Control, untreated mice; Rx, pazopanib-treated mice.
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and treated mice varied from 20 to 69 ng/ml, which is within the re-
ported range for murine plasma (27-96 ng/ml). No significant changes
in soluble VEGFR-2 in treated versus control mice were detected for 5-
and 15-day treatment groups (Figure 6A). The levels of soluble VEGFR-1
varied within one order of magnitude, from 220 to 2220 pg/ml,
and seemed to be below the expected range of soluble VEGFR-1
in murine plasma (2750-8026 pg/ml). However, no significant changes
in sVEGFR-1 in treated versus control mice were detected for 5- and
15-day treatment groups (Figure 6B).
Discussion
Variable responses of individual patients to cancer therapy have stim-
ulated the development of noninvasive imaging methods that can de-
tect early treatment response [31,32]. A recent report demonstrated
that changes in [18F] 2-fluoro-2-deoxy-D-glucose (FDG) positron
emission tomography (PET) tracer uptake can detect response to che-
motherapy as early as 24 hours after the onset of treatment [33]. Cur-
rently, downstream effects of VEGFR-directed therapy are imaged in
clinic by computed tomography and dynamic contrast-enhanced mag-
netic resonance imaging. Several clinical trials are in progress to deter-
mine the utility of PET imaging of tumor metabolism with 18F-FDG
and 18F-FLT, and αvβ3 integrins with
18F-RGD-peptide based tracers
(www.clinicaltrials.gov). However, as important as downstream mark-
ers are, molecular imaging of the drug target itself provides critical
information on the target prevalence, opening opportunities for treat-
ment management and optimization. This is particularly true for the
development of antiangiogenic therapies, where the lack of suitable
noninvasive methods for monitoring the drug’s target is the critical
barrier in the evaluation of new antiangiogenic therapies [5].
We report here that the intricate temporal dynamics of VEGFR-2 re-
sponse to pazopanib treatment can be readily measured with scVEGF/
99mTc by SPECT imaging. Our SPECTand autoradiography data indi-
cate that in the HT29 tumor model, pazopanib induces a very rapid de-
crease in tracer uptake even before pazopanib-induced changes in tumor
size. As judged by immunohistochemical analyses of VEGFR-2 and pan-
endothelial CD31 markers, the decrease in tracer uptake coincides with
a remarkable depletion of CD31+/VEGFR-2+ ECs in tumor vasculature.
A similar rapid regression of tumor vasculature in other murine tumor
Figure 4. Effects of pazopanib treatment on immunostaining for VEGFR-1, VEGFR-2, and CD31. (A–D) Images of representative micros-
copy fields (objective, ×5) with fluorescent double immunostaining for indicated markers and merged images with counterstaining for
nuclei at panels A and D. (A) Control tumor. (B) Control tumor, representative field from the tumor interior. (C) Control tumor, represen-
tative field from the tumor edge with higher density of markers. (D) Five-day pazopanib-treated tumor. Tumor edge on the right is visible
on the merged panel. (E) Images of representative fields with chromogenic staining for CD31 and VEGFR-2 obtained from three indi-
vidual mice after a 15-day pazopanib treatment and three time-matched control mice; objective, ×4. (F) Pazopanib treatment does not
affect VEGFR-1. Images of representative fields with immunostaining for VEGFR-1 (green) and counterstaining for nuclei (blue) from
control and pazopanib-treated mice. Bar, 20 μm.
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xenograft models has also been reported for other VEGFR-2 tyrosine
kinase inhibitors, such as sorafenib [10], sunitinib [11], and AZD2171
[12]. However, as treatment continues, scVEGF/99mTc uptake in-
creases, as judged by both SPECT imaging and autoradiography. Cor-
respondingly, immunohistochemical analyses indicate reestablishment
ofCD31+/VEGFR-2+ ECs at the tumor edges. It should be noted that
immunohistochemical evidence of the overall tumor revascularization
either after antiangiogenic drug withdrawal [15,16,20,21] or after long
treatment with anti–VEGFR-2 antibody [34] has been reported. How-
ever, our imaging results seem to suggest a rather rapid and localized re-
establishment of CD31+/VEGFR-2+ ECs at the tumor edges only.
Taken together, our data indicate that scVEGF/99mTc SPECT imaging
faithfully reflects the temporal and spatioselective response of VEGF re-
ceptors to pazopanib treatment.
Currently, there is an intense interest in the mechanisms of actions
of drugs that target VEGF/VEGFR signaling, as well as in the mech-
anisms responsible for resistance to such drugs, named adaptive/evasive
resistance, which lead to vascular resurgence [7,35]. The appearance
of highly vascularized areas at the tumor edges supports a continuous
tumor growth and even supports metastatic dissemination [20,21,36].
It is expected that revascularization would play a critical role in re-
sponse to drugs targeting VEGF/VEGFR signaling not only in mouse
models but also in cancer patients [37].
Conversely, revascularization might provide for better delivery of
chemotherapeutic drugs to tumor growth areas, justifying the combi-
nation regimens and particularly metronomic combinations [38,39].
We are currently extending our imaging studies to establish the pat-
terns of VEGFR changes in various multidrug treatment regimens.
To the best of our knowledge, we present here the first direct real-
time evaluation of the complex dynamics of VEGFR expression in
response to a VEGFR-targeted therapy. In principle, imaging with
scVEGF-based tracers can be extended to human use providing
for new opportunities in evidence-based treatment management of
VEGFR-targeted therapies including patient selection, dose optimi-
zation, and rational design of combination regimens. For example,
scVEGF/99mTc tracer uptake at the early stages of treatment might de-
fine the preexisting drug target levels and characterize the drug target
depletion. Nevertheless, resurgence of scVEGF/99mTc tracer uptake
might suggest a better timing for combination or metronomic therapy
and/or emerging resistance to VEGF/VEGFR inhibitors throughout
the course of treatment.
What are the foreseeable barriers in the translation of VEGFR
imaging with scVEGF/99mTc into clinic? First, there are indications
that SPECT imaging might be less advantageous than PET imaging
with respect to spatial resolution and possibly contrast-to-noise ratios
[40]. From this prospective, it might bemore beneficial to develop tracers
based on scVEGF–polyethylene glycol–DOTA conjugate [22] that can
be radiolabeled with 99mTc for SPECT, 64Cu and 68Ga for PET im-
aging, as well as with therapeutic radionuclides. Second, scVEGF-based
tracers might be incompatible with one of the most widely used VEGF/
VEGFR–directed drugs, anti-VEGF antibody bevacizumab (Avastin).
Fortunately, it was reported that a single G88A substitution in human
VEGF eliminates Avastin binding without affecting VEGF affinity to
VEGFR [41]. Thus, if necessary,minor reengineering of scVEGFwould
make scVEGF-based tracers suitable for monitoring treatments with
bevacizumab. Third, there are legitimate concerns associated with short-
Figure 4. (continued).
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and long-term physiological effects of scVEGF-based tracers. Although
only detailed safety studies with can address these concerns, past clini-
cal trials suggest that several infusions of recombinant VEGF165 at
0.05 μg/kg per minute for 20minutes are well tolerated [42]. Assuming
the same safety profile for scVEGF-based tracers, this dosage would be
more than sufficient for injection of ∼10 mCi of tracer with a readily
achievable specific activity of ∼200 μCi/μg. Taken together; these con-
siderations suggest that technical barriers for using scVEGF/99mTc can
be overcome. Although only clinical trials can establish clinical relevance
and predictive value of any biomarker [43], we expect that VEGFR
imaging will be useful for surveillance and evaluation of responses to
VEGF/VEGFR–directed therapies.
Figure 5. Pazopanib treatment induced a dramatic decrease in CD31 and VEGFR-2 immunohistochemical staining in intratumoral vas-
culature. (A, B) Representative high-magnification (40× oil) microscopy field with double-fluorescent immunostaining for CD31 (red) and
VEGFR-2 (green) of the tumor center area. Bar, 20 μm. (A) Five-day pazopanib treatment and time-matching control; (B) 15-day pazopanib
treatment and time-matching control. (C) Quantitative analysis of immunostaining for CD31 and VEGFR-2 in high-magnification fields
(n = 5). Counterstaining for nuclei with DAPI (blue). Control, untreated mice; Rx, pazopanib-treated mice.
Figure 6. Pazopanib does not induce statistically significant changes in the levels of soluble VEGF receptors. sVEGFR-2 (A) and sVEGFR-1
(B) in plasma of HT29 tumor-bearing mice. Control, untreated mice; Rx, pazopanib-treated mice.
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